Medicus Pharma Ltd

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. It focuses on identifying, acquiring, and advancing relatively de-risked clinical stage assets through clinical development and commercialization. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX), a biotechnology company specializing in non-invasive dermatological treatments, is gearing up for a pivotal year in 2025. The company is advancing SkinJect, its flagship asset for basal cell carcinoma, while planning significant expansions to its drug pipeline.

Medicus Pharma CEO charts course for 2025 with clinical milestones for SkinJect

Earlier this week Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that its innovative skin patch treatment has received Minor Use and Minor Species (MUMS) designation from the FDA. The patch, which uses a cellulose-based, doxorubicin-loaded design, is aimed at treating squamous cell carcinoma in horses.

Medicus Pharma achieves FDA MUMS approval for equine squamous cell carcinoma patch - ICYMI

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) announced that the Food and Drug Administration has granted Minor Use in Major Species (MUMS) designation for its Investigational New Animal Drug, a dissolvable Doxorubicin-containing microneedle array (D-MNA) patch targeting external squamous cell carcinoma in horses. The MUMS designation, akin to the Orphan Drug status for human medicine, provides Medicus with a seven-year exclusive marketing period following product approval or conditional approval, contingent on meeting the program's requirements.

Medicus Pharma's horse skin cancer treatment wins MUMS designation from FDA

Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses Company to Submit Product Development Plan to Treat External Squamous Cell Carcinoma (SCC) in Horses

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma (NASDAQ:MDCX, TSX-V:MDCX) provided an update on its phase two clinical trial for a novel non-invasive treatment targeting basal-cell carcinoma.  CEO Raza Bokhari told Proactive that 25% of patient recruitment for the U.S.-based trial has been completed.

Medicus Pharma CEO on basal-cell carcinoma trial progress – ICYMI

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced that its Phase 2 clinical study targeting basal cell carcinoma (BCC) is now being conducted at nine clinical sites across the United States, with more than 25% of the 60 patients expected to be enrolled in the study already randomized. An interim data analysis is planned for Q1 2025, and Medicus intends to submit these findings to the US Food and Drug Administration (FDA) to request a Type C meeting in Q2 2025, the company said on Monday.

Medicus Pharma eyes pivotal trial for novel skin cancer therapy as Phase 2 enrollment progresses

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) announced it has entered into an agreement with healthcare consulting firm Swanielle to explore expanding its Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) into the Asia-Pacific region. The collaboration aims to identify potential pharmaceutical or biotech partners in Southeast Asia to facilitate this expansion.

Medicus Pharma partners with Swanielle to expand basal cell carcinoma study into Asia-Pacific

Provides Update on SKNJCT-003 Phase 2 Clinical Study for Treatment of Nodular Basal Cell Carcinoma (BCC) Currently Underway in United States Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - December 2, 2024) - Medicus Pharma Ltd. (NASDAQ: MDCX) (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region.

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in clinical development, medical affairs and drug safety, Medicus said on Monday.

Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer

Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D Program

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) CEO and chairman Raza Bokhari joined Proactive to discuss the company's recent listing on the Nasdaq, a key milestone for the biotechnology firm. Following their initial public offering (IPO) on the Nasdaq, Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) raised $4 million to fund its ongoing Phase 2 proof-of-concept trial for a promising noninvasive treatment for basal cell carcinoma, the most common form of skin cancer.

Medicus Pharma makes debut on Nasdaq raising $4M to advance skin cancer trial - ICYMI

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 15, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the closing of its previously announced initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share.

Medicus Pharma Ltd. Announces Closing of US$4.0M Initial Public Offering in the United States

Medicus Pharma (TSX-V:MDCX) announced the pricing of its US initial public offering (IPO), with 970,000 units priced at $4.125 per unit. Each unit will comprise one common share and one warrant, which are exercisable at $4.64 and have a five-year expiry.

Medicus Pharma announces pricing of US IPO

Toronto, Ontario and Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Medicus Pharma Ltd (NASDAQ: MDCX) (TSXV: MDCX) (the "Company") today announced the pricing of its initial public offering in the United States of 970,000 units, at a price of US$4.125 per unit. Each unit consists of one common share of the Company and one warrant to purchase one common share.

Medicus Pharma Ltd. Announces Pricing of US$4.0M Initial Public Offering in the United States

News for Medicus Pharma Ltd Stock (MDCX)